HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.

Abstract
Cardiovascular diseases (CVD) have overtaken infectious diseases and are currently the world's top killer. A quite strong linkage between this type of ailments and elevated plasma levels of triglycerides (TG) has been always noticed. Notably, this risk factor is mired in deep confusion, since its role in atherosclerosis is uncertain. One of the explanations that aim to decipher this persistent enigma was provided by apolipoprotein C-III (apoC-III), a small protein historically recognized as an important regulator of TG metabolism. Preeminently, hundreds of studies have been carried out in order to explore the APOC3 genetic background, as well as to establish a correlation between its variants and dyslipidemia-related disorders, pointing to an earnest predictive power for future outcomes. Among several polymorphisms reported within the APOC3, the SstI site in its 3'-untranslated region (3'-UTR) was the most consistently and robustly associated with an increased CVD risk. As more genetic data supporting its importance in cardiovascular events aggregate, it was declared, correspondingly, that apoC-III exerts various atherogenic effects, either by intervening in the function and catabolism of many lipoproteins, or by inducing endothelial inflammation and smooth muscle cells (SMC) proliferation. This review was designed to shed the light on the structural and functional aspects of the APOC3 gene, the existing association between its SstI polymorphism and CVD, and the specific molecular mechanisms that underlie apoC-III pathological implications. In addition, the translation of all these gathered knowledges into preventive and therapeutic benefits will be detailed too.
AuthorsIsraa Dib, Alia Khalil, Racha Chouaib, Yolla El-Makhour, Hiba Noureddine
JournalMolecular biology reports (Mol Biol Rep) Vol. 48 Issue 1 Pg. 875-886 (Jan 2021) ISSN: 1573-4978 [Electronic] Netherlands
PMID33389539 (Publication Type: Journal Article, Review)
Chemical References
  • 3' Untranslated Regions
  • APOC3 protein, human
  • Apolipoprotein C-III
  • Cardiovascular Agents
  • ISIS 304801
  • Oligonucleotides
  • Triglycerides
Topics
  • 3' Untranslated Regions
  • Apolipoprotein C-III (antagonists & inhibitors, blood, genetics)
  • Atherosclerosis (blood, drug therapy, genetics, pathology)
  • Cardiovascular Agents (therapeutic use)
  • Clinical Trials as Topic
  • Gene Expression
  • Humans
  • Hyperlipoproteinemia Type I (blood, drug therapy, genetics, pathology)
  • Hypertriglyceridemia (blood, drug therapy, genetics, pathology)
  • Oligonucleotides (therapeutic use)
  • Plaque, Atherosclerotic (blood, drug therapy, genetics, pathology)
  • Polymorphism, Genetic
  • Risk Factors
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: